Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| ARRY | Array BioPharma Inc. | 0.16% | 46.50 | 8.1% | $739.78m | |
| AMGN | Amgen Inc. | 0.32% | 176.69 | 1.3% | $505.23m | |
| CELG | Celgene Corporation | 0.01% | 91.77 | 1.3% | $444.24m | |
| GILD | Gilead Sciences, Inc. | -1.41% | 67.11 | 0.9% | $405.67m | |
| BIIB | Biogen Inc. | -0.33% | 232.84 | 1.3% | $386.37m | |
| ILMN | Illumina, Inc. | -0.06% | 302.10 | 3.5% | $335.57m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.13% | 297.80 | 2.6% | $277.78m | |
| SRPT | Sarepta Therapeutics, Inc. | -2.84% | 152.45 | 14.7% | $202.93m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.58% | 123.76 | 2.0% | $199.31m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.09% | 176.53 | 1.9% | $187.65m | |
| EXAS | Exact Sciences Corporation | -0.29% | 115.85 | 24.1% | $140.08m | |
| A | Agilent Technologies, Inc. | -1.12% | 69.76 | 1.6% | $133.75m | |
| INCY | Incyte Corporation | -1.32% | 80.32 | 2.5% | $114.57m | |
| BLUE | Bluebird Bio, Inc. | -1.55% | 133.65 | 14.3% | $97.67m | |
| BMRN | BioMarin Pharmaceutical Inc. | -1.86% | 82.43 | 4.3% | $87.70m |
Company Profile
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.